Clinical Trials Browser

Phase 1/2 × Recruiting × NETWORK × Clear all

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT04870944 2026-02-24

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

81 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT06078813 2025-04-30

Spine-SABR

Phase 1/2 Recruiting

126 enrolled

Other solid neoplasm

Solid Tumor Spine Metastases

NCT06635330 2024-10-10

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Phase 1/2 Recruiting

5 enrolled

Lymphoid

Burkitt Lymphoma, Recurrence